Re: Farmas USA
¿Has visto esta otra new para SNTA????
LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 12, 2013-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2013 ECCO-ESMO-ESTRO European Cancer Congress in Amsterdam, The Netherlands.
“Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels”
Abstract #: 3416
Date and Time: September 29, 2:00 – 4:30 PM CEST
Presenter: Dean Fennell, M.D., Ph.D., University of Leicester, United Kingdom
Interim results from the on-going GALAXY-1 Phase 2b/3 trial that were previously presented at ASCO 2013 will be reviewed. Additional details on the outcomes of patient subgroups with mutated KRAS and elevated LDH will also be provided.
Synta expects that results from a future analysis of the GALAXY-1 trial will be presented at the 2013 World Conference on Lung Cancer in Sydney, Australia during the week of October 27.
“Antimetastatic activity of ganetespib: Preclinical studies and assessment of progressions due to new lesions in the GALAXY-1 NSCLC trial”
Abstract #: 3517
Date: September 29, 2:00 – 4:30 PM CEST
Presenter: Vojo Vukovic, M.D., Ph.D., Synta Pharmaceuticals
Results demonstrating the anti-angiogenic and anti-metastatic properties of ganetespib in preclinical cancer models will be presented.